Introduction
Tumor suppressor proteins act through a variety of mechanisms to control the process of cell proliferation, including suppression of cell division, induction of apoptosis, and identification and repair of damaged DNA (1) . Deactivation of the tumor suppressor protein p53 is critical for the development of many tumors (2) . Serdemetan (JNJ-26854165) is a novel tryptamine derivative that was originally isolated in a p53-activating screen designed to detect increased cellular expression of p53. While initial studies suggested activity as an inhibitor of human double minute-2 oncogene (HDM2), subsequent studies demonstrated anti-proliferative activity in both TP53 wild-type and mutant tumor models, with equivalent potencies regardless of p53 status (3) . Serdemetan inhibits proliferation of cell lines derived from multiple solid tumor types, with IC 50 in the low micromolar range, and has demonstrated potent in vivo antitumor activity in non-small cell lung, breast, colon, prostate and glioblastoma cancer xenograft models. It induced p53-mediated apoptosis in acute leukemia cells with wild-type TP53 (3) . Micro-array analysis of a wild-type TP53 tumor cell line response to various anti-cancer drugs demonstrated that serdemetan induces a gene expression profile similar to that of chemotherapeutic agents known to interfere with DNA synthesis and induce S-phase arrest (3) . While the exact mechanism of action remains under investigation, the observed activities of serdemetan in preclinical models suggest that it may have efficacy in the treatment of cancer.
The primary objectives of this first-in-human, phase 1 study were to explore the safety and pharmacokinetic (PK) profiles of serdemetan, and to determine its dose limiting toxicities (DLTs) and maximum tolerated dose (MTD) in patients with advanced malignancies. A key secondary objective was to explore the pharmacodynamic (PD) effects on the p53-dependent
Research.
on July 14, 2017. © 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on August 10, 2011; DOI: 10.1158/1078-0432. CCR-11-1101 pathways in sequential tumor and skin biopsies as well as in blood samples in order to better characterize the recommended phase II dose for further development.
Patients and Methods

Study population
Patients of either sex, ≥18 years of age, with advanced, refractory solid malignancies were eligible for the study. All patients were required to have histological or cytological confirmation of malignancy, an Eastern Cooperative Oncology Group (ECOG) performance status score ≤2, and adequate bone marrow, liver, and renal function.
Patients were excluded from the study if they had central nervous system metastasis, uncontrolled heart disease or hypertension,or psychiatric illness incompatible with study participation. After the initial instances of QTc prolongation were observed, stricter criteria excluding patients at increased risk for QTc prolongation (clinically significant rhythm or conduction abnormality, congenital long QT syndrome, QTc at screening >450 msec, structural heart disease, liver impairment, and family history of long QT syndrome or sudden death before age 40 years) were introduced by protocol amendment. Recent, ongoing, or expected medical therapy with amiodarone or warfarin excluded patients from participation in the study.
An Independent Ethics Committee at each study site approved the protocol. This study was conducted in accordance with the Declaration of Helsinki, consistent with Good Clinical Practices and applicable regulatory requirements. All patients provided written informed consent
Author Manuscript Published OnlineFirst on August 10, 2011; DOI: 10.1158/1078-0432. CCR-11-1101 to participate in the study. A Data Review Committee (DRC) was installed to ensure optimum study conduct.
Study design
This phase 1 study was conducted from December 2006 to February 2010 at 5 study centers in Belgium and Spain. It included a 14-day screening phase, an open-label treatment phase consisting of 21-day cycles, and an end-of-study visit within 14 days after the last dose.
The study was divided into two parts, a dose escalation phase (Part 1) and an expansion phase (Part 2). Serdemetan was administered orally, starting with a 4 mg/day dose, with subsequent doses escalated in a 3+3 dose escalation scheme, to determine the MTD. The starting dose was initially calculated at 8 mg, based on the human equivalent dose of one-sixth of the lowest dose in the rat (the most sensitive species) that does not cause severe irreversible toxicity, while daily dosing was deemed optimal for a proposed HDM2 inhibitor. The starting dose was subsequently reduced to 4mg daily, at the request of Belgium Health Authorities. Up to three additional patients were added if one patient exhibited a DLT within the first cycle of therapy (DLT period). Further dose escalation was halted if at least 2 out of a maximum of 6 patients within a cohort exhibited a DLT. Intrapatient dose escalations were allowed to minimize early cohort exposure to sub-therapeutic doses.
To minimize exposure of patients to dose levels predicted to lack therapeutic potential, a pharmacokinetically guided dose escalation (PGDE (4-5)) was initially pursued, in which dose increments of up to 500% were allowed. Once the drug-drug interaction safe level (DDISL) of
on July 14, 2017. © 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 9 50 ng/mL maximum plasma concentration (C max ) had been achieved, an adapted "modified Fibonacci" scheme (6-7) was pursued, in which dose increases of 10 to 100% were allowed. The DRC convened after every dose cohort had completed the DLT period, and at additional time points if necessary, to review all available safety, PK, and PD data. If unacceptable toxicity occurred in patients after the DLT period, dose de-escalations were permitted.
During Part 2 of the study, additional patients were enrolled to increase the number of patients evaluated for safety, PK, and PD profiles of serdemetan, at doses and schedules that were candidates for phase II studies. At least 12 evaluable patients for each dose or schedule were to be investigated.
During cycle 1, study investigations (PK, PD, and toxicity assessments) were carried out on days -1, 1, 3, 7, 10, 14 and 21; interim safety evaluations were performed on days 3, 7, 10 and 14.
Interim safety evaluations were performed on days 3, 10 and 21 of cycle 2 and on day 21 of subsequent cycles. During cycle 2, PD sampling was carried out on day 21. Tumor response assessments were performed on day 21 of every alternate treatment cycle, from cycle 2 onwards. Liquid formulation was initially used to allow for maximum dose flexibility during early dose escalation. Serdemetan solution was used for doses up to 300 mg/day during once-daily dosing schedule and capsules were used for doses above 300 mg/day, for both once-daily and twice- 
Safety evaluations
Safety assessments included monitoring for treatment-emergent adverse events (TEAEs), DLTs, clinical laboratory tests (hematology, coagulation, blood chemistry, and urinalysis), vital signs, physical examinations, and carotid duplex ultrasound scan (pre-clinical studies had suggested carotid artery contraction). Electrocardiograms (ECG) were obtained at each specified clinic visit and analysis, and multiple gated acquisition (MUGA) scans were performed at the conclusion of each cycle to monitor cardiac function while on study.
Adverse events were evaluated in accordance with National Cancer Institute Common Terminology Criteria, Version 3.0 (8), and were monitored up to 30 days after the last dose of study drug.
Pharmacokinetic evaluations
Blood and urine sample collection
Venous blood samples (3 mL) were collected on days 1 and 21 at 0. Food effect and drug-drug interactions were also investigated as part of this study, but will be reported separately.
Bioanalytical procedures
Plasma and urine concentrations of serdemetan were determined using a validated liquid 
Pharmacodynamic evaluations
The study was designed to investigate parameters of serdemetan activity, based upon its demonstrated ability to induce p53 (and based upon its originally proposed mechanism of action as an HDM2 inhibitor). These parameters included p53 and Ki67 levels detected via immunohistochemical staining, and serum levels of macrophage inhibitory cytokine-1(MIC-1) protein. Skin biopsies (at baseline and on day 21 of cycle 1) and tumor biopsies (on day 21 of cycle 1) were collected from patients expected to achieve serum C max concentrations greater than 100 ng/mL and 195 ng/mL, respectively, for analysis of p53 and Ki67. Levels of MIC-1 were evaluated using enzyme-linked immunosorbent assay (ELISA) of venous blood samples (5 mL), collected at baseline and on days 3, 10, and 21 in cycle 1, on day 21 in subsequent cycles, and at the end of treatment. 
Statistical analysis
The PK analysis set included patients who completed the PK assessments on day 1 of cycle 1.
The safety analysis set included all patients who received at least one dose of serdemetan.
Descriptive statistics was used to summarize safety and efficacy results. The plasma concentration time-curves were used to estimate C max , time to reach maximum plasma concentration (t max ), area under the concentration-time curve (AUC) from time 0 to 24 hours (AUC 24h ) for day 1 and 21, and additionally the AUC from time 0 to infinity (AUC ∞ ) for day 1. For all evaluated doses, the effective half-lives (t 1/2 ) were estimated on the basis of the accumulation ratio between day 1 and 21. The relationship between plasma concentrations and QTcF (corrected QT using Fridericia's formula) values was evaluated on the basis of all data for which blood samples were taken immediately after ECG recording.
Results
Patient disposition and baseline characteristics
The majority (59.2%) of patients was male, most (98.6%) were white and 97.2% of patients had an ECOG performance status score of 0 or 1 at the time of study entry ( Table 1 ). The most frequent tumor types were colorectal cancers, sarcomas, and melanomas.
Of the 71 enrolled patients, 62 were treated in the dose escalation phase (Part 1): Fifty one patients were on a once-daily dosing schedule, and 11 were on a twice-daily dosing schedule.
Nine patients were treated in the expansion phase (Part 2). A summary of the dose escalations, and the observed dose limiting toxicities, is provided in Table 2 .
The median (range) number of administered cycles was 2 the 14 patients who did not receive 2 cycles, the reported reasons for discontinuation included disease progression (6), adverse event (5), and subject choice (3).
Forty-seven (66.2%) patients discontinued the study due to disease progression, 10 (14.1%) discontinued by their own choice, 9 (12.7%) discontinued after an adverse event, 3 (4.2%) discontinued due to unsatisfactory therapeutic benefits, 1 (1.4%) discontinued due to new primary malignancy, and 1 (1.4%) discontinued due to close out of the trial.
Safety
The first DLT observed during dose escalation occurred in the 300 mg daily cohort, when 1 patient of the first 4 treated (one patient did not complete the first cycle of therapy) experienced a Grade 3 QTc prolongation (Table 2) . When subsequent expansion of this cohort to 3 additional patients failed to demonstrate any additional DLTs, dose escalation proceeded until the 400 mg daily dose was reached, at which time 2 of the 3 patients treated experienced DLTs. As a result, the 350 mg daily dose cohort was further expanded with 4 patients. Although there were no observed DLTs in any patient in this expansion cohort, one patient did require dose deescalation. This fact, and concern over the potential of QTc prolongation as toxicity, prompted further expansion of the 300 mg daily dose cohort with 9 additional patients, all of which were treated without any additional observed DLTs. Thus, with the absence of any observed DLTs at the 350 mg dose (Table 2) , 350 mg daily was identified as the protocol-defined MTD.
In light of the observed QTc prolongation in the daily dosing schedule, a twice-daily dosing escalation was also performed in the expectation that a lowered C max might mitigate the risk of [n=1]; anemia and thrombocytopenia [n=1]). Ten (14.1%) patients experienced QTcF increases >60 msec from baseline, of which 5 patients showed QTcF >500 msec. The relatively frequent observation of QTc prolongation prompted a more thorough examination of this toxicity.
Correlation of QTc changes with corresponding plasma levels of serdemetan suggested a positive correlation (Fig. 1C) .
Eight (11.3%) patients died during the study due to general physical health deterioration (n=3); central nervous system metastases (n=1); lung infection and pyrexia (n=1); dyspnea (n=1); pneumonia (n=1); or intestinal obstruction (n=1). All deaths were considered either not related, or unlikely related, to study drug by the investigators.
Pharmacokinetics
Serdemetan was rapidly absorbed after oral administration, with C max generally observed 2-3 hours after administration of the solution, and 3-4 hours after administration of capsules (Supplementary Table 1 , Fig. 1A and1B) . At 24 hours after once-daily dosing, levels were less than half of their peak values. Plasma concentrations reached steady-state after 10 days of dosing, with no further accumulation observed through day 21. After a single dose, and at steady-state, serdemetan exposure as expressed by C max and AUCs increased doseproportionally. At steady-state, C max and AUC 0-24 h were 3 to 4 times higher than after single dose indicating an effective t 1/2 in the order of 2 to 3 days. The mean steady-state C max was 2,330 ng/mL after 300 mg once-daily dosing and slightly lower after 150 mg twice-daily dosing.
Overall, inter-patient variability (CV%) was low (<50%) for all exposure parameters for both dosing schedules. Less than 10% of the daily dose of serdemetan was recovered as parent drug in urine. The mean renal clearance was 1 L/h. Changes in QTcF were directly related to serdemetan plasma concentrations (Fig. 1C) . Steadystate C max concentrations after 300 mg once daily dosing caused QTcF changes of on average >25 msec.
Pharmacodynamics
Biomarker studies provided evidence of serdemetan activity in both surrogate and tumor biopsy tissue. The p53 levels in skin biopsies increased on day 21, compared with day 1. The increase was exposure-related ( Fig. 2) , with higher levels of nuclear p53 staining observed in skin biopsies taken from patients with higher AUC exposures. . Conversely, Ki67 levels in skin biopsies decreased from day 1 to 21, but this was observed at the 300 mg/day dose only.
Evidence of response in tumors was less robust. Significant increases in p53 expression were only observed in 8 patients out of 13 from whom the tumor biopsies were collected. No significant changes in Ki67 levels were observed relative to baseline in these tumor specimens.
A dose dependent increase in serum MIC-1 levels was measured as a potential PD marker of serdemetan induced p53 activation. Serdemetan treatment reliably resulted in increase of MIC-1 serum levels at day 21 compared to baseline, however the magnitude of the effect was not observed to be dose dependent.
Efficacy
Of the 71 patients treated in this study, 57 were evaluable for efficacy, having had both a baseline and at least one post-treatment study performed for comparison. Of the 14 nonevaluable patients, 6 were reported to have discontinued as a result of an adverse event, 6 as a 
result of disease progression, and 2 by patient choice. One patient with breast cancer, receiving serdemetan 150 mg twice-daily, showed a partial response (this patient also reported 102% increase in p53 levels in tumor biopsies) (Fig. 3B) . Seven additional patients exhibited a decrease in tumor size, but did not meet criteria for partial response. Twenty-two (38.6%) patients had stable disease as their best overall response (evaluated as per RECIST guideline), with four of these patients exhibiting prolonged stable disease with extended courses of serdemetan therapy (of 126, 196, 308, and 420 days in patients with angiosarcoma, breast cancer, Hurthle cell carcinoma, and ependymoma, respectively). Thirty-four (59.6%) patients had progressive disease as their best overall response. The maximum tumor reduction in all patients receiving doses above 150 mg/day, the threshold that resulted in p53 induction in skin biopsies, is shown in Fig.   3A .
Discussion
Serdemetan is a novel tryptamine derivative that was originally isolated in a chemical screen, based upon its ability to induce p53 expression. Initial pre-clinical studies suggested that its mechanism of action included the inhibition of HDM2, but continued investigations, conducted in parallel with this trial, recently disproved this hypothesis by demonstrating that serdemetan was similarly active in cell lines and xenografts lacking p53 function, or in HDM2-deficient experimental models. Although it's exact mechanism of action remains under investigation, its ability to induce S phase arrest and apoptosis in a wide range of tumor models, independent of p53 status, has been repeatedly demonstrated.
This first-in-human study of serdemetan evaluated incremental doses of serdemetan in order to identify the DLTs, and the MTDs, for both once-daily and twice-daily dosing schedules. Safety, 
PK and PD (using biomarker studies) profiles of serdemetan were characterized; efficacy data for antitumor activity was also collected.
Serdemetan was rapidly absorbed after oral administration when given as a solution or capsule.
Capsules showed a lag time of 0.5 to 1 hour, followed by rapid absorption that was similar to absorption from the solution. Steady-state exposure was achieved within 10 days of daily administration of serdemetan. The elimination of serdemetan was slower than anticipated, as indicated by the overall effective t 1/2 of 2-3 days, in contrast to pre-clinical studies, where the elimination t 1/2 was 3-8 hrs in rats, mice and dogs (data not shown).
The MTD of serdemetan was found to be 350 mg for once-daily schedule and 150 mg for twicedaily schedule. The main DLT reported was Grade 3 QTc prolongation (observed in 4 patients).
Grade 2 QTc prolongation was observed in 10 additional patients, identifying QTc prolongation as the primary safety concern associated with serdemetan therapy. QTc prolongation was directly correlated with serdemetan plasma concentration. The other DLTs included rash, pruritis, and tremor. Though 8 deaths occurred during the study, all were considered to be unlikely related to serdemetan therapy by the study investigator.
Lymphopenia was observed in the majority of patients and >20% patients experienced Grade 3 or 4 severity. The TEAEs of anemia, thrombocytopenia, and neutropenia were minimal, indicating that serdemetan has little effect on bone marrow, and therefore might be used in combination with existing cytotoxic chemotherapies. Although >30% patients experienced Grade suggesting that true incidence rate for this toxicity may be lower than that was observed.
Although the MTD was determined to be 350 mg daily, as defined by the protocol, the next lower dose of 300 mg daily was recommended for subsequent phase II studies, in light of the observed dose-dependent nature of the QTc prolongation ( Figure 1C) , and the similar PK profiles of the 350 mg and 300 mg doses observed in this study ( Figure 1B) .
Biomarker analyses performed before and after the serdemetan therapy showed dose-dependent increase in p53 levels in skin biopsies, from doses 150 mg/day onwards. Though the number of samples available for tumor biomarker analysis was limited, a trend towards p53 induction in tumors was observed. Thus, the observation of serdemetan-induced p53 expression in human tumors in this study is consistent with pre-clinical studies demonstrating similar activity in both cell lines and xenograft models. Serum levels of MIC-1, a marker of p53 activation, were seen to rise after treatment with serdemetan, however the increase was not dose-dependent, and therefore MIC-1 levels were considered to be a poor pharmacodynamic marker for serdemetan.
Serdemetan showed a modest clinical activity based on the results of antitumor assessment, with one patient with advanced breast cancer exhibiting a partial response. Interestingly, a 102% increase in p53 staining was observed in the tumor of this patient. The disease remained stable in approximately 40% of patients. Some of these patients with stable disease received extended courses of serdemetan therapy, at doses that reliably induced p53 in skin biopsies. These findings, in addition to the other observed minor responses, suggest a direct effect of serdemetan on at least a subset of tumors.
Research. 
